tiprankstipranks
Jounce Therapeutics (JNCE)
NASDAQ:JNCE
Holding JNCE?
Track your performance easily

Jounce Therapeutics (JNCE) Technical Analysis

0 Followers

Technical Sentiment

Overall Consensus
Buy
13Bullish
2Neutral
5Bearish
Technical Analysis Consensus
Buy
5Bullish
2Neutral
1Bearish
Moving Average Consensus
Buy
8Bullish
0Neutral
4Bearish
Jounce Therapeutics’s (JNCE) Moving Averages Convergence Divergence (MACD) indicator is <0.01, suggesting Jounce Therapeutics is a Buy.
Jounce Therapeutics’s (JNCE) 20-Day exponential moving average is 1.88, while Jounce Therapeutics’s (JNCE) share price is $1.88, making it a Buy.
Jounce Therapeutics’s (JNCE) 50-Day exponential moving average is 1.85, while Jounce Therapeutics’s (JNCE) share price is $1.88, making it a Buy.

Jounce Therapeutics (JNCE) Pivot Points

Nov 26, 2024, 04:03 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.81
1.85
1.86
1.90
1.91
1.95
1.96
Fibonacci
1.85
1.87
1.88
1.90
1.92
1.93
1.95
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Jounce Therapeutics (JNCE) Moving Averages

Nov 26, 2024, 04:03 PM
Period
Simple
Exponential
MA5
1.88Buy
1.88Sell
MA10
1.88Buy
1.88Sell
MA20
1.88Sell
1.88Buy
MA50
1.88Buy
1.85Buy
MA100
1.74Buy
1.81Buy
MA200
1.55Buy
1.93Sell
Jounce Therapeutics’s (JNCE) 10-Day exponential moving average is 1.88, while Jounce Therapeutics’s (JNCE) share price is $1.88, making it a Sell.
Jounce Therapeutics’s (JNCE) 100-Day exponential moving average is 1.81, while Jounce Therapeutics’s (JNCE) share price is $1.88, making it a Buy.
Jounce Therapeutics’s (JNCE) stock price is $1.88 and Jounce Therapeutics’s (JNCE) 50-day simple moving average is 1.88, creating a Buy signal.
Jounce Therapeutics’s (JNCE) stock price is $1.88 and Jounce Therapeutics’s (JNCE) 100-day simple moving average is 1.74, creating a Buy signal.
Jounce Therapeutics’s (JNCE) stock price is $1.88 and Jounce Therapeutics’s (JNCE) 200-day simple moving average is 1.55, creating a Buy signal.

Jounce Therapeutics (JNCE) Technical Indicators

Nov 26, 2024, 04:03 PM
Name
Value
Implied Action
RSI (14)
59.27
Neutral
STOCH (9,6)
>-0.01
Buy
STOCHRSI (14)
<0.01
Buy
MACD (12,26)
<0.01
Buy
ADX (14)
35.61
Neutral
Williams %R
-100.00
Buy
CCI (14)
0.00
-
ATR (14)
0.05
-
Ultimate Oscillator
>-0.01
Sell
ROC
0.00
-
Jounce Therapeutics’s (JNCE) Relative Strength Index (RSI) is 59.27, creating a Neutral signal.
Jounce Therapeutics’s (JNCE) Trend Strength Indicator (ADX) is 35.61, creating a Neutral signal.

FAQ

Is JNCE a Buy, Hold, or Sell?
Based on JNCE’s technical indicators, JNCE is a Buy.
    What is JNCE’s RSI (14)?
    JNCE’s RSI (14) is 59.27, which suggests JNCE is a Neutral.
      What is JNCE’s MACD?
      JNCE’s MACD is <0.01, which suggests JNCE is a Buy.
        What is JNCE’s 5-day moving average?
        JNCE’s 5-day moving average is 1.88, which suggests JNCE is a Buy.
          What is JNCE’s 20-day moving average?
          JNCE 20-day moving average is 1.88, which suggests JNCE is a Sell.
            What is JNCE’s 50-day moving average?
            JNCE’s 50-day moving average is 1.88, which suggests JNCE is a Buy.
              What is JNCE’s 200-day moving average?
              JNCE’s 200-day moving average is 1.55, which suggests JNCE is a Buy.
                What is JNCE’s Williams % R (14)?
                JNCE’s Williams % R (14) is -100.00, which suggests JNCE is a Buy.
                  What is JNCE’s CCI (14)?
                  Currently, no data Available
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis